CN116574809A - 检测癌症复发的方法 - Google Patents
检测癌症复发的方法 Download PDFInfo
- Publication number
- CN116574809A CN116574809A CN202310693406.1A CN202310693406A CN116574809A CN 116574809 A CN116574809 A CN 116574809A CN 202310693406 A CN202310693406 A CN 202310693406A CN 116574809 A CN116574809 A CN 116574809A
- Authority
- CN
- China
- Prior art keywords
- cancer
- nucleic acid
- mutation
- motif
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903456A AU2015903456A0 (en) | 2015-08-26 | Methods of detecting cancer recurrence | |
| AU2015903456 | 2015-08-26 | ||
| PCT/AU2016/050799 WO2017031551A1 (en) | 2015-08-26 | 2016-08-26 | Methods of detecting cancer recurrence |
| CN201680062714.2A CN108603231B (zh) | 2015-08-26 | 2016-08-26 | 检测癌症复发的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680062714.2A Division CN108603231B (zh) | 2015-08-26 | 2016-08-26 | 检测癌症复发的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116574809A true CN116574809A (zh) | 2023-08-11 |
Family
ID=58099416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310693406.1A Withdrawn CN116574809A (zh) | 2015-08-26 | 2016-08-26 | 检测癌症复发的方法 |
| CN201680062714.2A Active CN108603231B (zh) | 2015-08-26 | 2016-08-26 | 检测癌症复发的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680062714.2A Active CN108603231B (zh) | 2015-08-26 | 2016-08-26 | 检测癌症复发的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11225690B2 (https=) |
| EP (1) | EP3341496B1 (https=) |
| JP (1) | JP6850294B2 (https=) |
| CN (2) | CN116574809A (https=) |
| AU (1) | AU2016310415B2 (https=) |
| ES (1) | ES2873841T3 (https=) |
| WO (1) | WO2017031551A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016310415B2 (en) | 2015-08-26 | 2022-04-21 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
| EP3500966B1 (en) | 2016-08-25 | 2021-04-21 | Nantomics, LLC | Immunotherapy markers and uses therefor |
| EP3710600B1 (en) * | 2017-11-17 | 2025-03-12 | GMDx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| CN108796077B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 |
| WO2021243401A1 (en) * | 2020-06-01 | 2021-12-09 | Gmdx Co Pty Ltd | Methods of predicting cancer progression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| ES2674928T3 (es) * | 2012-11-05 | 2018-07-05 | Gmdx Co Pty Ltd | Métodos para determinar la causa de la mutagénesis somática |
| AU2016310415B2 (en) | 2015-08-26 | 2022-04-21 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
-
2016
- 2016-08-26 AU AU2016310415A patent/AU2016310415B2/en active Active
- 2016-08-26 ES ES16838136T patent/ES2873841T3/es active Active
- 2016-08-26 CN CN202310693406.1A patent/CN116574809A/zh not_active Withdrawn
- 2016-08-26 WO PCT/AU2016/050799 patent/WO2017031551A1/en not_active Ceased
- 2016-08-26 US US15/754,983 patent/US11225690B2/en active Active
- 2016-08-26 CN CN201680062714.2A patent/CN108603231B/zh active Active
- 2016-08-26 EP EP16838136.6A patent/EP3341496B1/en active Active
- 2016-08-26 JP JP2018529689A patent/JP6850294B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3341496A1 (en) | 2018-07-04 |
| CN108603231A (zh) | 2018-09-28 |
| JP2018531620A (ja) | 2018-11-01 |
| US20200232038A1 (en) | 2020-07-23 |
| AU2016310415A1 (en) | 2018-04-19 |
| CN108603231B (zh) | 2023-06-30 |
| ES2873841T3 (es) | 2021-11-04 |
| JP6850294B2 (ja) | 2021-03-31 |
| EP3341496B1 (en) | 2021-02-24 |
| EP3341496A4 (en) | 2019-03-27 |
| AU2016310415B2 (en) | 2022-04-21 |
| US11225690B2 (en) | 2022-01-18 |
| WO2017031551A1 (en) | 2017-03-02 |
| HK1260327A1 (en) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020223754B2 (en) | Methods and materials for assessing loss of heterozygosity | |
| JP6900314B2 (ja) | 膀胱癌の治療、診断、及び予後判定方法 | |
| US20230138572A1 (en) | Method for determining the likelihood that a subject has or will develop cancer | |
| CN108603231B (zh) | 检测癌症复发的方法 | |
| JP2006520197A (ja) | チミジレートシンターゼ遺伝子座におけるヘテロ接合性の喪失に基づいて化学療法計画を決定する方法 | |
| Kumar et al. | Evaluation of fibroblast growth factor receptor 3 (FGFR3) and tumor protein P53 (TP53) as independent prognostic biomarkers in high-grade non-muscle invasive bladder cancer | |
| EP2460891A1 (en) | Prognostic marker for mamma carcinoma | |
| HK1260327B (en) | Methods of detecting cancer recurrence | |
| KR102325356B1 (ko) | 유사유전자를 이용한 신경교종의 악성도 진단용 조성물 및 이의 이용 | |
| HK40120571A (en) | Methods and materials for assessing loss of heterozygosity | |
| HK1259439B (en) | Methods for determining the cause of somatic mutagenesis | |
| Aboalela | Acquired epigenetic and chromosomal changes in women treated for breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230811 |
|
| WW01 | Invention patent application withdrawn after publication |